Bedaquiline (BQ)-containing regimen at the programmatic level for MDR-TB: preliminary results Source: International Congress 2017 – Treatment of multi-drug-resistant tuberculosis (MDRTB): where are we now? Year: 2017
Pharmacokinetics and drug susceptibility testing imply limited activity of current regimens for Mycobacterium avium complex disease Source: Annual Congress 2012 - Non-tuberculous and tuberculous mycobacterial infections: from epidemiology to clinical findings Year: 2012
An audit of adherence to antituberculous drugs using a new, rapid, point of care test for isoniazid metabolites Source: Eur Respir J 2002; 20: Suppl. 38, 566s Year: 2002
The role of somatostatin analogues in combination to antineoplastic agents in the treatment of SCLC patients (preliminary findings) Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009
Experimental justification choise to prevent hepatotoxic reactions to anti-TB drugs based on gene-phenotypic characteristics Source: International Congress 2019 – Tuberculosis: diagnosis Year: 2019
The experience of overcome of Mcb.tuberculosis resistance to antituberculosis drugs Source: Eur Respir J 2002; 20: Suppl. 38, 613s Year: 2002
Evaluation of prophylactic observations efficacy and the quality of TB treatment using a math model for primarily revealed patients Source: Eur Respir J 2004; 24: Suppl. 48, 722s Year: 2004
Classification of antituberculosis drugs: a new proposal based on the most recent evidence Source: Eur Respir J 2015; 46: 887-893 Year: 2015
Pre-chemotherapy drug sensitivity test for antitubercular drugs in India – is it essential? Source: Eur Respir J 2005; 26: Suppl. 49, 649s Year: 2005
Long-term results of drug resistant tuberculosis treatment Source: Eur Respir J 2006; 28: Suppl. 50, 378s Year: 2006
Initial antituberculosis drugs resistance Source: Eur Respir J 2006; 28: Suppl. 50, 12s Year: 2006
The side effects of anti-tuberculosis treatment: a retrospective analysis Source: Eur Respir J 2002; 20: Suppl. 38, 369s Year: 2002
The comparative analysis of treatment effectiveness in children and adolescents with MDR TB with anti-TB drugs of the first and second lines Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology II Year: 2012
Availability of drug susceptibility testing to new/re-purposed anti-tuberculosis drugs: a TBnet study Source: Virtual Congress 2021 – Advances in the diagnosis of tuberculosis, multidrug-resistant tuberculosis and nontuberculous mycobacterial disease Year: 2021
Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance Source: Eur Respir J 2012; 39: 802-804 Year: 2012
The evidence regarding early antifungal treatment Source: International Congress 2018 – Fungal infection in the intensive care unit Year: 2018
Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007